Sharda Cropchem Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
SHARDACROP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sharda Cropchem's board approved audited consolidated and standalone financial results for FY25 (ended March 31, 2025). Consolidated revenue from operations jumped ~36.6% YoY to Rs. 4,319.85 crore (from Rs. 3,163.02 crore), driven mainly by the agrochemicals segment which grew to Rs. 3,772.97 crore from Rs. 2,639.43 crore. Net profit surged to Rs. 304.42 crore from just Rs. 31.91 crore last year (about 9.5x), pushing EPS to Rs. 33.74 vs Rs. 3.53. EBITDA margin expanded meaningfully as profit before tax rose over 5x to Rs. 378.34 crore. Statutory auditors B S R & Co. LLP gave an unqualified opinion on both consolidated and standalone results, and the company has zero outstanding borrowings. The board recommended a final dividend of Rs. 6.00 per share (face value Rs. 10), subject to shareholder approval.
Strong earnings beat with revenue and profit growth well above peers, clean audit report, and a reasonable dividend make this a positive filing for shareholders. Stock may see a positive reaction on strong profitability and improved margins, though the prior-year base was unusually low.